Document is current
Any future updates will be listed below
-
Authors
Clemmensen, Frederikke Kragh
Gramkow, Mathias Holsey
Simonsen, Anja Hviid
Ashton, Nicholas J.
Huber, Hanna
Blennow, Kaj
Zetterberg, Henrik
Waldemar, Gunhild
Hasselbalch, Steen Gregers
Frederiksen, Kristian Steen
- License Information
-
More Information
Article History
Received: 17 September 2024
Accepted: 20 December 2024
First Online: 21 January 2025
Declarations
:
: The study was approved by the Danish Research Ethics Committee (H-21044863) and followed the tenets of the 1975 Helsinki Declaration. The study was registered at clinicaltrials.gov (NCT05175664). Written informed consent was obtained from each participant prior to enrolment.
: Not applicable.
: KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KF serves on a scientific advisory board for Novo Nordisk and Eisai, has given lectures in symposia for Novo Nordisk, and has served or serves as principal investigator in trials for Roche, Biogen, AbbVie, Novo Nordisk and Roche Diagnostics for which fees is paid to the institution and no personal remuneration is received. KF also serves as Editor-in-Chief for Alzheimer´s Research and Therapy (Springer) for which personal remuneration is paid. The other authors have no conflict of interest to report.
